Congress hands Trump power to slash drug tariffs with minimal oversight
S. 998 — Medical Supply Chain Resiliency Act · Filed by Thom Tillis (R-NC) · 3 cosponsors · Introduced Mar 12, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes the President to negotiate trade agreements with countries that meet certain criteria (rule of law, IP protection, open trade during health emergencies) to reduce tariffs and trade barriers on medical goods and pharmaceuticals. The goal is to diversify U.S. medical supply sources away from over-reliance on China, Mexico, and Malaysia, and to harmonize regulatory standards across partner countries. Congress retains a 30–120 day review window to disapprove any agreement before it takes effect.
Why we flagged it
The bill's core function is to grant the President fast-track authority to negotiate and implement trade agreements on medical goods with minimal congressional friction. While framed as supply-chain resilience, it is fundamentally a delegation of trade-negotiation power with a 30–120 day congressional veto window—a procedural mechanism that favors executive action.
What the text implies
- Regulatory harmonization provisions (section 5(c)(3)) may lock the U.S. into adopting foreign regulatory standards for drug approval, potentially lowering safety or efficacy review thresholds to match lower-cost producers.
- IP protection harmonization (section 5(c)(5)) could extend patent protections and limit generic drug competition, raising long-term drug costs for consumers despite short-term tariff reductions.
The full analysis lists 5 implications of this text.
Who stands to gain
large pharmaceutical manufacturers (Merck, Pfizer, Johnson & Johnson); medical device makers (Medtronic, Boston Scientific, Stryker); contract manufacturers in lower-cost countries (India, Malaysia, Mexico)